New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

03-04-2021 08:40

CONCLUSIONS

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494)

Read abstract in NEJM

Adjuvant Nivolumab in Esophageal Cancer — A New Standard of Care (Editorial in NEJM; subscription required)

Zurück

Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.

News

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58

Go to the ELCC/ESMO 2021 PRESS RELEASE

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15

Go to the ELCC/ESMO 2021 PRESS RELEASE

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47

ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

22-03-2021 11:06

Read more

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

22-03-2021 10:58

Read more

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

08-02-2021 10:02

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO

News

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Einen Kommentar schreiben

News